Condition: Lymphoma, Extranodal NK-T-Cell · EBV · Sponsor: Cell Medica Ltd
To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Dana-Farber Cancer Center | Boston, Massachusetts, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| The Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | — |
| Baylor College of Medicine | Houston, Texas, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Universitaire Ouest | Paris, France | — |
| Centre Hospitalier de Lyon | Pierre-Bénite, France | — |
| Samsung Medical Center | Seoul, South Korea | — |
| Asan Cancer Center | Seoul, South Korea | — |
| University College London Hospital | London, UK, United Kingdom | — |
| The Christie Clinic | Manchester, UK, United Kingdom | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01948180